1-7 of 7
Richard H. Wilson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma

Katrina S. Pedersen, Nathan R. Foster, Michael J. Overman, Patrick M. Boland, Sunnie S. Kim, Kathryn A. Arrambide, Brandy L. Jaszewski, Tanios Bekaii-Saab, Rondell P. Graham, Jack Welch, Richard H. Wilson, Robert R. McWilliams
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (13): 3641–3648.
https://doi.org/10.1158/1078-0432.CCR-21-0159
Published: 01 July 2021
View article titled, ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma
Open the PDF for ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer

Philip D. Dunne, Sonali Dasgupta, Jaine K. Blayney, Darragh G. McArt, Keara L. Redmond, Jessica-Anne Weir, Conor A. Bradley, Takehiko Sasazuki, Senji Shirasawa, Tingting Wang, Supriya Srivastava, Chee Wee Ong, Ken Arthur, Manuel Salto-Tellez, Richard H. Wilson, Patrick G. Johnston, Sandra Van Schaeybroeck
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1): 230–242.
https://doi.org/10.1158/1078-0432.CCR-15-0603
Published: 03 January 2016
View article titled, EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Open the PDF for EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Victor Moreno García, David Olmos, Carlos Gomez-Roca, Philippe A. Cassier, Rafael Morales-Barrera, Gianluca Del Conte, Elisa Gallerani, Andre T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5663–5671.
https://doi.org/10.1158/1078-0432.CCR-14-0719
Published: 13 November 2014
View article titled, Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Open the PDF for Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

Simon Pacey, Richard H. Wilson, Mike Walton, Martin M. Eatock, Anthea Hardcastle, Anna Zetterlund, Hendrik-Tobias Arkenau, Javier Moreno-Farre, Udai Banerji, Belle Roels, Heidi Peachey, Wynne Aherne, Johan S. de Bono, Florence Raynaud, Paul Workman, Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1561–1570.
https://doi.org/10.1158/1078-0432.CCR-10-1927
Published: 15 March 2011
View article titled, A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models

Wendy L. Allen, Vicky M. Coyle, Puthen V. Jithesh, Irina Proutski, Leanne Stevenson, Cathy Fenning, Daniel B. Longley, Richard H. Wilson, Michael Gordon, Heinz-Josef Lenz, Patrick G. Johnston
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6647–6655.
https://doi.org/10.1158/1078-0432.CCR-08-0452
Published: 16 October 2008
View article titled, Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models
Open the PDF for Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models in another window
Includes: Supplementary data
Journal Articles

BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy

Jennifer E. Quinn, Colin R. James, Gail E. Stewart, Jude M. Mulligan, Patricia White, Gary K.F. Chang, Paul B. Mullan, Patrick G. Johnston, Richard H. Wilson, D. Paul Harkin
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (24): 7413–7420.
https://doi.org/10.1158/1078-0432.CCR-07-1083
Published: 19 December 2007
View article titled, BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy
Open the PDF for BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy in another window
Journal Articles

Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor

Susannah J. Stanway, Atul Purohit, L.W. Lawrence Woo, Saulat Sufi, David Vigushin, Rebecca Ward, Richard H. Wilson, Frank Z. Stanczyk, Nicola Dobbs, Elena Kulinskaya, Moira Elliott, Barry V.L. Potter, Michael J. Reed, R. Charles Coombes
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (5): 1585–1592.
https://doi.org/10.1158/1078-0432.CCR-05-1996
Published: 06 March 2006
View article titled, Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor
Open the PDF for Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor in another window